科伦博泰生物-B Sichuan Kelun-Biotech Biopharmaceutical (6990 HK) 25 年业绩回顾：商业化推进顺利；核心品种海外商业化兑现在即 FY25 Results Review: Rapid Sales Ramp-up in China; Core Products Set for Imminent Overseas Commercialization [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 研究报告 Research Report 24 Mar 2026 评级 优于大市 OUTPERFORM 现价 HK$421.00 目标价 HK$529.97 HTI ESG 3.0-3.0-3.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$68.53bn / US$8.75bn 日交易额 (3 个月均值) US$29.34mn 发行股票数目 162.77mn 自由流通股 (%) ...

研究报告 Research Report 24 Mar 2026 科伦博泰生物-B Sichuan Kelun-Biotech Biopharmaceutical (6990 HK) 25 年业绩回顾：商业化推进顺利；核心品种海外商业化兑现在即 FY25 Results Review: Rapid Sales Ramp-up in China; Core Products Set for Imminent Overseas Commercialization [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$421.00 目标价 HK$529.97 HTI ESG 3.0-3.0-3.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$68.53bn / US$8.75bn 日交易额 (3 个月均值) US$29.34mn 发行股票数目 162.77mn 自由流通股 (%) ...